FRAZER, Pa., Oct. 30 /PRNewswire-FirstCall/ -- Cephalon, Inc.
(Nasdaq: CEPH) today announced that its Analyst Day in New York City, to be
held on November 5, 2008, will be webcast live on the investor relations
section of its website at http://www.cephalon.com.
Cephalon's senior management will review the company's business strategy,
marketing plan and research and development initiatives. The presentations
will be delivered on Wednesday, November 5, 2008 beginning at approximately
12:30 p.m. EST and ending at 3:15 p.m. EST. The webcast will be archived for
one week following the broadcast. To access the webcast, log on to the
company's website at http://www.cephalon.com and click on "Investors," then
"Webcast." Click on the link and follow the prompts for registration and
access.
About Cephalon, Inc.
Founded in 1987, Cephalon, Inc. is an international biopharmaceutical
company dedicated to the discovery, development and commercialization of
innovative products in four core therapeutic areas: central nervous system,
pain, oncology and addiction. A member of the Fortune 1000, Cephalon currently
employs approximately 3,000 people in the United States and Europe. U.S. sites
include the company's headquarters in Frazer, Pennsylvania, and offices,
laboratories or manufacturing facilities in West Chester, Pennsylvania, Salt
Lake City, Utah, and suburban Minneapolis, Minnesota. The company's European
headquarters are located in Maisons-Alfort, France.
The company's proprietary products in the United States include:
TREANDA(R) (bendamustine hydrochloride) for Injection, AMRIX(R)
(cyclobenzaprine hydrochloride extended-release capsules), PROVIGIL(R)
(modafinil) Tablets [C-IV], FENTORA(R) (fentanyl buccal tablet) [CII],
TRISENOX(R) (arsenic trioxide) injection, VIVITROL(R) (naltrexone for
extended-release injectable suspension), GABITRIL(R) (tiagabine
hydrochloride), NUVIGIL(TM) (armodafinil) Tablets [C-IV] and ACTIQ(R) (oral
transmucosal fentanyl citrate) [C-II]. The company also markets numerous
products internationally. Full prescribing information on its U.S. products is
available at http://www.cephalon.com or by calling 1-800-896-5855.
In addition to historical facts or statements of current condition, this
press release may contain forward-looking statements. Forward-looking
statements provide Cephalon's current expectations or forecasts of future
events. These may include statements regarding anticipated scientific progress
on its research programs; development of potential pharmaceutical products;
interpretation of clinical results; prospects for regulatory approval;
manufacturing development and capabilities; market prospects for its products;
sales, adjusted net income and basic adjusted income per common share
guidance; and other statements regarding matters that are not historical
facts. You may identify some of these forward-looking statements by the use of
words in the statements such as "anticipate," "estimate," "expect," "project,"
"intend," "plan," "believe" or other words and terms of similar meaning.
Cephalon's performance and financial results could differ materially from
those reflected in these forward-looking statements due to general financial,
economic, regulatory and political conditions affecting the biotechnology and
pharmaceutical industries as well as more specific risks and uncertainties
facing Cephalon such as those set forth in its reports on Form 8-K, 10-Q and
10-K filed with the U.S. Securities and Exchange Commission. Given these risks
and uncertainties, any or all of these forward-looking statements may prove to
be incorrect. Therefore, you should not rely on any such factors or forward-
looking statements. Furthermore, Cephalon does not intend to update publicly
any forward-looking statement, except as required by law. The Private
Securities Litigation Reform Act of 1995 permits this discussion.
